Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | ANPEP | P15144 | 1/20 | 0.31 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CRHBP | P24387 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14969740 | 1.00 | RNPEP (0.33) | RNPEPLMNAALDH1A1GAAANPEP | |
| SCHEMBL14144142 | 0.83 | RNPEP (0.31) | RNPEPLMNAGAA | |
| SCHEMBL4572445 | 0.83 | RNPEP (0.38) | RNPEPLMNAALDH1A1GAAANPEP | |
| SCHEMBL12652258 | 0.81 | LMNA (0.35) | RNPEPLMNAALDH1A1GAAANPEP | |
| SCHEMBL13347807 | 0.81 | RNPEP (0.36) | RNPEPLMNAANPEPENPEP | |
| SCHEMBL24681882 | 0.81 | LMNA (0.35) | RNPEPLMNAALDH1A1GAAANPEP | |
| SCHEMBL12949275 | 0.81 | TSHR (0.35) | RNPEPLMNAALDH1A1GAAANPEP | |
| SCHEMBL6009013 | 0.81 | TSHR (0.35) | RNPEPLMNAANPEPENPEPMEN1 | |
| SCHEMBL17244399 | 0.81 | RNPEP (0.32) | RNPEPLMNAALDH1A1GAAANPEP | |
| SCHEMBL18880875 | 0.81 | RNPEP (0.32) | RNPEPLMNAALDH1A1GAAANPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 268 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9827289-B2 | Flagellin related polypeptides and uses thereof | CLEVELAND CLINIC FOUNDATION (US) | 2017-11-28 | — | — | US | disclosed |
| EP-3239153-A1 | 9-(1H-IMIDAZOL-5-YL)-1,11-DIHYDROISOCHROMENO[4',3':6,7]NAPHTHO[1,2-D]IMIDAZOLE DERIVATIVES AND THEIR USE AS INHIBITORS OF HCV NS5A | Gilead Pharmasset LLC (US) | 2017-11-01 | — | — | EP | disclosed |
| US-20170240930-A1 | Methods and Systems for Removing Undissolved Solids Prior to Extractive Fermentation in the Production of Butanol | BUTAMAX ADVANCED BIOFUELS LLC (US) | 2017-08-24 | — | — | US | disclosed |
| EP-2502073-B1 | REDUCING LEUKOCYTE INTERFERENCE IN COMPETITIVE IMMUNOASSAYS | ABBOTT POINT OF CARE INC (US) | 2017-08-23 | — | — | EP | disclosed |
| EP-2720715-B1 | VACCINE COMPOSITION COMPRISING AN INACTIVATED CHIKUNGUNYA VIRUS STRAIN | BHARAT BIOTECH INT LTD (IN) | 2017-08-09 | — | — | EP | disclosed |
| EP-2635710-B1 | OPTICAL ANALYTE DETECTION SYSTEMS AND METHODS OF USE | GENALYTE INC (US) | 2017-08-09 | — | — | EP | disclosed |
| US-20170202948-A1 | VACCINE COMPOSITIONS HAVING IMPROVED STABILITY AND IMMUNOGENICITY | NOVAVAX, INC. (US) | 2017-07-20 | — | — | US | disclosed |
| EP-2640719-B1 | ANTIVIRAL COMPOUNDS | GILEAD PHARMASSET LLC (US) | 2017-05-10 | — | — | EP | disclosed |
| US-9555008-B2 | Synthesis of hyperbranched amphiphilic polyester and theranostic nanoparticles thereof | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) | 2017-01-31 | — | — | US | disclosed |
| US-20170003305-A1 | METHOD, COMPOSITION AND DEVICE FOR SAMPLING NATRIURETIC PEPTIDES IN A BIOLOGICAL FLUID | CRIMSON U.S. ASSETS LLC (US) | 2017-01-05 | — | — | US | disclosed |
| EP-1666476-B1 | A process for purification of proanthocyanidin oligomers | KYOWA HAKKO KOGYO KK (JP) | 2008-01-16 | — | — | EP | disclosed |
| US-20080004337-A1 | Therapeutic Agent for Substance Dependence | FUJIMOTO CO., LTD. (JP) | 2008-01-03 | — | — | US | disclosed |
| EP-1865542-A1 | EXPOSURE APPARATUS, EXPOSURE METHOD, AND DEVICE PRODUCTION METHOD | Nikon Corporation (JP) | 2007-12-12 | — | — | EP | disclosed |
| US-20070225350-A1 | Compositions and methods for treating neoplastic diseases | TRIPHASE RESEARCH AND DEVELOPMENT I CORP. (CA) | 2007-09-27 | — | — | US | disclosed |
| EP-1777234-A2 | Methods of treatment of inflammatory diseases using specific binding agents of human angiopoietin - 2 | Amgen Inc. (US) | 2007-04-25 | — | — | EP | disclosed |
| US-7205121-B2 | DEP-1 receptor protein tyrosine phosphatase interacting proteins and related methods | COLD SPRING HARBOR LABORATORY (US) | 2007-04-17 | — | — | US | disclosed |
| EP-1414953-B1 | IDENTIFICATION AND CLONING OF THE RECEPTOR GENE FOR SYMBIOTIC NITROGEN FIXATION | MTA SZEGEDI BIOLOG KOEZPONT (HU) | 2007-04-11 | — | — | EP | disclosed |
| US-7196163-B2 | Assays using amyloid precursor proteins with modified β-secretase cleavage sites to monitor β-secretase activity | MERK & CO., INC. (US) | 2007-03-27 | — | — | US | disclosed |
| US-20070027634-A1 | Molecular hepatotoxicology modeling | OCIMUM BIOSOLUTIONS, INC. | 2007-02-01 | — | — | US | disclosed |
| US-20070003617-A1 | Morphine controlled release system | EGALET A/S | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004337-A1 | Therapeutic Agent for Substance Dependence | OPRM1, GABARAP, OPRK1 | RNPEP 1346/4885LMNA 4843/4885ALDH1A1 190/4885 |
| US-20070225350-A1 | Compositions and methods for treating neoplastic diseases | PSMG3, PSME3, PSMC5 | RNPEP 1521/4885LMNA 535/4885ALDH1A1 4490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.